Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02920398 · ClinicalTrials.gov registry record · Phase 1
A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02920398 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 21 participants.
The verdict
NCT02920398, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Investigating single dose pharmacokinetics and safety of turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process in patients with severe haemophilia A
Interventions
- DRUG turoctocog alfa pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-10-04 |
| Est. Completion | 2017-04-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02920398
The ClinicalTrials.gov registry entry for NCT02920398 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which turoctocog alfa pegol is the first listed.
NCT02920398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02920398 about?
NCT02920398 is a clinical study titled "A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A". Investigating single dose pharmacokinetics and safety of turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process in patients with severe haemophilia A
What is the current status of trial NCT02920398?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2016-10-04. Estimated completion is 2017-04-07.
What interventions are being tested in trial NCT02920398?
The interventions under investigation include: turoctocog alfa pegol (DRUG).
Who is sponsoring clinical trial NCT02920398?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.